Mayo Clinic Laboratories > Renal > Glomerular disease > Membranous nephropathy

MEmbranous nePHropathy

Classify subtype, guide therapy, and monitor responses

Membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome in adults. Our comprehensive menu of clinically validated pathology- and serum-based assays assists with diagnosis, monitors disease progression, and guides clinical outcomes.

70%-80%

70%–80% of underlying antigens can be identified by our MSMN test

Membranous nePHropathy test menu

Serum-based testing Serum-based testing
Tissue-based testing Tissue-based testing

Serum-based testing

We offer a comprehensive menu of clinically validated serum-based assays to assist with the diagnosis of MN, monitor disease progression, and guide clinical outcomes.

Key testing

Algorithm View the PMND1 cascade
Learn more Membranous nephropathy classification

Highlights

Membranous nephropathy assay: PMND1

John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a condition that can lead to kidney failure.

Learn more

Tissue-based testing 

Our new, one-of-a-kind mass spectrometry membranous nephropathy panel can identify 13 different antigens, which can help a physician diagnose, treat, or assess prognosis for their patients.

Key testing

  • MSMN | Membranous Nephropathy Target Antigen Identification, Mass Spectrometry, Tissue
    • This panel uses laser microdissection of the kidney tissue followed by tandem mass spectrometry, which can determine the underlying target antigen in 70%–80% of MN cases.
    • Provides physicians with more answers than are currently available using traditional IF/IHC stains.
    • This method requires significantly less kidney tissue to complete vs. individual IF/IHC stained slides, which can be helpful in cases where limited tissue is available.

Additional testing

Highlights

Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D.

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

Learn more
Testing for a surprising antigen enables insight into a chronic kidney illness

Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.

Learn more
NELL-1 [Test in Focus]

Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and insight on disease expression.

Learn more
References
  1. Sethi S, Beck LH, Glassock RJ, et all. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int. December 2023;104(6):1092-1102.
  2. Sethi S, Madden B. Mapping antigens of membranous nephropathy: almost there. Kidney Int. March 2023; 103(3):469-472.
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.